Cantor Fitzgerald Weighs in on Mesoblast FY2025 Earnings

Mesoblast Limited (NASDAQ:MESO) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Mesoblast in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($0.70) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Mesoblast’s current full-year earnings is ($0.70) per share.

Several other equities analysts have also recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $24.00 target price (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Stock Down 7.7 %

MESO stock opened at $13.68 on Thursday. Mesoblast has a twelve month low of $2.05 and a twelve month high of $22.00. The business has a 50 day moving average price of $17.94 and a two-hundred day moving average price of $12.33. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC boosted its position in Mesoblast by 241.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 35,191 shares of the company’s stock worth $697,000 after purchasing an additional 24,870 shares during the period. Bank of America Corp DE boosted its holdings in shares of Mesoblast by 1,503.3% during the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company’s stock worth $5,756,000 after buying an additional 272,595 shares during the period. BNP Paribas Financial Markets grew its stake in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock valued at $51,000 after buying an additional 2,597 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in Mesoblast in the 4th quarter valued at about $88,000. Finally, Jump Financial LLC acquired a new stake in Mesoblast during the fourth quarter worth approximately $205,000. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.